DexCom, Inc. filings document formal disclosures for its continuous glucose monitoring and glucose biosensing business. Recent 8-K reports cover quarterly and annual financial results, preliminary financial outlook, revenue by geography, operating income, non-GAAP measures, and exhibits containing earnings releases.
Dexcom proxy and governance filings address annual meeting matters, board composition, committee assignments, director independence, executive compensation, pay-versus-performance disclosures, equity awards, indemnity arrangements, and leadership-related compensation terms. The filing record also reflects material-event reporting for board appointments and other governance changes.
DexCom, Inc. (DXCM) – Form 4 insider transaction
EVP & Chief HR Officer Sadie Stern reported the sale of 1,466 common shares on 26-Jun-2025 at an average price of $85.06, generating gross proceeds of roughly $125,000. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted 20-Feb-2025, signalling that timing was automated rather than discretionary.
Following the sale, Stern’s beneficial ownership stands at 108,155 shares, of which 74,450 are unvested RSUs scheduled to vest between 2026 and 2028. The reported sale represents ~1.4% of her post-transaction holdings, leaving her overall exposure to DexCom equity largely intact.
No derivative transactions, option exercises, or additional sales were disclosed, and there is no indication of strategic changes or financial performance data within this filing.
DexCom (NASDAQ: DXCM) Officer Sadie Stern has filed a Form 144 notice indicating a proposed sale of 1,466 shares of common stock with an aggregate market value of $124,697.96. The planned transaction is scheduled for execution on June 26, 2025, through Morgan Stanley Smith Barney LLC.
The shares to be sold were acquired as Restricted Stock from the issuer on November 19, 2023. The filing also discloses Stern's recent trading activity, showing three previous sales in May 2025 totaling 6,184 shares with combined gross proceeds of $526,318.38.
The transaction is being executed under a Rule 10b5-1 trading plan adopted on February 20, 2025. As of the filing date, DexCom has 392,107,501 shares outstanding. The seller has certified no knowledge of material adverse non-public information regarding the company's operations.
DexCom Director Mark G. Foletta reported significant insider trading activity through a pre-planned 10b5-1 sale. On June 16, 2025, Foletta's Family Trust sold 2,750 shares at a weighted average price of $83.129 per share, executed through multiple trades ranging from $82.635 to $83.61.
Following the transaction, Foletta maintains beneficial ownership of:
- 56,621 shares held indirectly through The Foletta Family Trust DTD 1/30/2015
- 5,731 unvested restricted stock units granted on May 8, 2025, which will vest on the earlier of the one-year anniversary or DexCom's 2026 Annual Meeting
The sale was executed under a 10b5-1 trading plan adopted by the Trust on March 13, 2025, designed to enable orderly disposition of shares. This transaction demonstrates planned insider selling activity while maintaining substantial equity position in the company.
On June 16, 2025, DexCom, Inc. (DXCM) Executive Vice President & Chief Legal Officer Michael Jon Brown sold 500 shares of common stock at $82.80 per share, according to a Form 4 filed on June 18, 2025. The trade was executed under a Rule 10b5-1 trading plan adopted on February 21, 2025, which pre-schedules transactions to reduce the appearance of information-based trading.
Following the sale, Brown’s beneficial ownership stands at 95,102 shares, including 86,490 unvested restricted stock units that vest through 2028. No derivative security activity was reported and there are no indications of changes in Brown’s role or corporate strategy. The 500-share sale represents roughly 0.5 % of his reported holdings and is immaterial relative to DexCom’s total public float.